Eli-Lily Picks Sankara Nethralaya

Eli-Lily and Company’s Ruboxistaurin Mesylate may reduce moderate visual loss in people with moderate to severe diabetic retinopathy. They have selected Sri Bhagwan Mahaveer Vitreoretinal Services of Sankara Nethralaya as one of the four centers in India to evaluate Ruboxistaurin Mesylate role in reducing the occurrence of center-threatening diabetic macular edema. The Sankara Nethralaya team includes Principal Investigator: Dr. Tarun Sharma, Ophthalmologist Incharge: Dr. Rajiv Raman, Physician Incharge: Dr. S Bhaskaran, Photographer: Mr. M.S. Krishna and Optometrist & Coordinator: Mr. D. Senthil Kumar.